Effects of a Phosphodiesterase inhibitor on the Browning of Adipose Tissue in Mice
Open Access
- 1 August 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (8) , 1852
Abstract
Cilostazol is a selective inhibitor of phosphodiesterase type 3 (PDE3) that increases intracellular cyclic adenosine monophosphate (cAMP), which plays a critical role in the development of the beige phenotype and the activation of its thermogenic program in white adipose tissue (WAT). We investigated the metabolic effects of PDE3B inhibition with cilostazol treatment in the adipose tissue of high-fat diet (HFD)-fed mice. Seven-week-old male C57BL/6J mice were randomly assigned to either the cilostazol or control group. The control group was divided into two groups: the chow diet and HFD. The expression of uncoupling Protein 1 (UCP1) and other brown adipocyte markers was compared. In the HFD-fed cilostazol group, C57BL/6J mice displayed improvements in systemic metabolism, including improved glucose tolerance and lipid profile, but only modest effects on body weight were observed. In the visceral WAT of HFD-fed cilostazol-treated mice, cAMP/protein kinase A (PKA) signaling pathways were activated, resulting in the “browning” phenotype, smaller fat deposits, and enhanced mRNA expression of UCP1 and other brown adipocyte markers. PDE3B appears to be an important regulator of lipid metabolism, insulin sensitivity, and thermogenic programs in adipose tissues. An increase in intracellular cAMP via PDE3B inhibition with cilostazol treatment promoted the browning of visceral WAT.Keywords
Funding Information
- Korea Otsuka Pharmaceutical Co., Ltd
This publication has 50 references indexed in Scilit:
- Myostatin knockout drives browning of white adipose tissue through activating the AMPK‐PGC1α‐Fndc5 pathway in muscleThe FASEB Journal, 2013
- Obesity as a Major Risk Factor for CancerJournal of Obesity, 2013
- Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developmentsBritish Journal of Pharmacology, 2012
- Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesityNutrition & Diabetes, 2011
- Brown Adipose Tissue in Humans Is Activated by Elevated Plasma Catecholamines Levels and Is Inversely Related to Central ObesityPLOS ONE, 2011
- Identification and Importance of Brown Adipose Tissue in Adult HumansNew England Journal of Medicine, 2009
- PRDM16 controls a brown fat/skeletal muscle switchNature, 2008
- Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B–null miceJournal of Clinical Investigation, 2006
- Regulatory circuits controlling white versus brown adipocyte differentiationBiochemical Journal, 2006
- Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular diseaseClinical and Experimental Medicine, 2003